GlassScriptPhysician profile
Sonia Shah
NPI 1720173743
$2,202.65
in general payments reported to CMS, 2019-2025
22 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $64.70 · 2021: $351 · 2022: $228 · 2023: $297 · 2024: $375 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $364.27 | 2025 | Rapiblyk |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $240.23 | 2019-2025 | Lifevest |
| Pfizer INC. | $236.58 | 2019-2025 | |
| Lantheus Medical Imaging, INC. | $192.62 | 2019-2025 | Definity |
| Janssen Pharmaceuticals, INC | $173.85 | 2019-2024 | Xarelto |
| Abiomed | $147.06 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $141.67 | 2021-2025 | Evkeeza |
| Amgen INC. | $96.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.13 | 2022-2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $78.61 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $64.18 | 2023-2024 | Camzyos |
| Astellas Pharma US INC | $60.00 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $59.57 | 2024 | |
| Merck Sharp & Dohme LLC | $57.39 | 2024 | Winrevair |
| United Therapeutics Corporation | $42.21 | 2023 | Tyvaso |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38.72 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $23.25 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $21.58 | 2022 | |
| Philips North America LLC | $20.34 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.96 | 2019 | |
| Scpharmaceuticals INC. | $18.24 | 2025 | |
| Boston Scientific Corporation | $16.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.